Inventor profile of:

Albert B. Deisseroth

City:

Potomac, Maryland

Country:

United States

Published Applications:

27

Last publication date:

2025-09-30

Top Assignees for applications by Albert B. Deisseroth

The entities that hold a legal rights for patent applications filed by inventor Deisseroth Albert B.:

Recent patent applications by Deisseroth Albert B.

Albert B. Deisseroth from Potomac, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-09-30
US17726801
Human necessities

SARS-CoV-2 fusion protein vaccine/regimen

#2 | 2024-06-13
US20240189422A1
Human necessities

COMBINATION CANCER THERAPY

#3 | 2023-08-03
US20230241193A1
Human necessities

mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES

#4 | 2022-05-12
US20220143171A1
Human necessities

CD40 LIGAND FUSION PROTEIN VACCINE

#5 | 2021-10-26
US15864268
Human necessities

Burkholderia pseudomallei composition

#6 | 2020-02-13
US20200046820A1
Human necessities

Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD40L/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells

#7 | 2019-10-01
US14724409
Human necessities

Dengue hemorrhagic fever virus vaccine

#8 | 2019-05-21
US14695445
Human necessities

Pharmaceutical compositions and methods of blocking

#9 | 2019-03-07
US20190070289A1
Human necessities

Combination cancer therapy

#10 | 2019-01-22
US15587777
Human necessities

TAA/CD4OL composition/vaccine for malaria

#11 | 2019-01-08
US14822178
Chemistry; metallurgy

Multivalent DNA composition for

#12 | 2019-01-01
US15689386
Human necessities

Vaccines for herpes simplex virus 1 and 2

#13 | 2018-12-11
US15375455
Human necessities

Composition and method against C-difficile

#14 | 2018-11-20
US15130041
Human necessities

TAA/ecdCD40L oncolytic virus

#15 | 2018-02-13
US15341389
Human necessities

Ebola virus composition/vaccine

#16 | 2017-08-24
US20170239339A1
Human necessities

Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells

#17 | 2017-06-29
US20170182147A1
Human necessities

CD40 ligand fusion protein vaccine

#18 | 2017-06-29
US20170182145A1
Human necessities

Methods and compositions for suppressing virulence of methicillin resistant

#19 | 2017-05-09
US14079830
Human necessities

TAA/CD40L vaccine for malaria

#20 | 2017-03-09
US20170065705A1
Human necessities

Adenoviral vector vaccine

#21 | 2016-12-27
US14690889
Human necessities

Methods and compositions for suppressing virulence of methicillin resistant

#22 | 2015-03-05
US20150064209A1
Chemistry; metallurgy

Methods for generating immunity to antigen

#23 | 2014-05-08
US20140127252A1
Human necessities

TULAREMIA-TAA/CD40L VACCINE

#24 | 2014-03-20
US20140080208A1
Chemistry; metallurgy

Adenoviral expression vector encoding a CD40L fusion protein

#25 | 2013-06-13
US20130149330A1
Human necessities

PHARMACEUTICAL COMPOSITIONS AND METHODS OF BLOCKING BACILLUS ANTHRACIS

#26 | 2012-11-01
US20120276148A1
Human necessities

Methods of generating immune responses with compositions comprising an adenoviral expression vector comprising a CD40L fusion protein

#27 | 2012-08-02
US20120195924A1
Human necessities

Composition comprising an adenoviral expression vector comprising a CD40L fusion protein for generating immune responses

InventorID:

285690 ⎘